RxDoctor Payments Data

Mark Dabagia, MD

Urology · Fort Wayne, INNPI 1891795852

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $23,050 of the $26,568 with a category attached, or 86.8%. Johnson & Johnson accounts for 82.6% of it on its own, with 8 other manufacturers making up the rest.

$26,568in general payments, 2019–2025

Across 52 payments — averaging $510.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22K
  • Intuitive Surgical$3K
  • Ethicon Endo-surgery Inc.$1K
  • AbbVie$82
  • Novartis$42
  • Axonics, Inc.$19
  • plus $40 from 3 others

What the payments were for

  • Consulting fees$23,05087%
  • Travel & lodging$1,2255%
  • Food & beverage$6973%
  • Education$1,5966%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(3 entities)27$21,935
Intuitive Surgical13$3,200
Ethicon Endo-surgery Inc.1$1,250
AbbVie5$82
Novartis2$42
Axonics, Inc.1$19
Urovant Sciences Inc1$16
Bayer1$12
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,568 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$191,146
Medicare patients
509
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide13$217,667
MyrbetriqMirabegron14$14,911
Finasteride364$4,318
Tamsulosin Hcl374$4,176
Bicalutamide44$1,160
Solifenacin Succinate13$452
Dutasteride11$391
Oxybutynin Chloride15$361
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$327
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim59$281
Cephalexin50$209
Ciprofloxacin Hcl75$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$21,935$217,66713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.

Other urology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →